MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020GlobeNewsWire • 11/04/20
MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference CallGlobeNewsWire • 10/28/20
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in BloodGlobeNewsWire • 09/22/20
MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with IncyteGlobeNewsWire • 09/21/20
MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020GlobeNewsWire • 09/20/20
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/01/20
MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial ResultsGlobeNewsWire • 07/30/20
MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference CallGlobeNewsWire • 07/23/20
Earnings Preview: MacroGenics (MGNX) Q2 Earnings Expected to DeclineZacks Investment Research • 07/22/20
MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric CancerGlobeNewsWire • 07/09/20
MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric CancerGlobeNewsWire • 06/05/20
MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid LeukemiaGlobeNewsWire • 06/03/20
MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast CancerGlobeNewsWire • 05/28/20
MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid LeukemiaGlobeNewsWire • 05/27/20
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual MeetingGlobeNewsWire • 05/13/20
Are Options Traders Betting on a Big Move in MacroGenics (MGNX) Stock?Zacks Investment Research • 05/12/20